WORK PACKAGE 2

Empowering the individual

Deciphering long-term outcomes

Innovative approaches to remote care

Managing of comorbidities

Pain mechanisms and management

Phenotyping for personalized medicine

Optimized medical interventions

The objective of WORK PACKAGE 2 is to identify biomarkers and genetic/epigenetic markers of treatment efficacy and disease severity, and to characterise and stratify early disease.

The work package will have technical responsibility for biobanking in the Clinical Trial Unit (CTU).

Work package managers

LEADER
Professor Hilde Berner Hammer, MD PhD
CO-LEADER
Senior researcher Guro Løvik Goll, MD PhD

Here you can read more about the projects included in or associated with WORKpackage 2.

WP1 - Optimized medical interventions

Remission in patients with rheumatoid arthritis: a randomized controlled trial investigating the use of ultrasound in clinical follow-up

Project manager

Espen A. Haavardsholm

WP1 - Optimized medical interventions

A Norwegian study comparing treatment strategies in rheumatoid arthritis after achieving long-term good disease control

Project manager

Espen A. Haavardsholm

WP2 - Phenotyping for personalized medicine

BIopsies of KnEejoint synovitis from RA or OA patients

Project manager

Hilde B. Hammer

WP2 - Phenotyping for personalized medicine

Experimental precision medicine

Project manager

Guro Løvik Goll

WP1 - Optimized medical interventions

Methotrexate in the treatment of erosive hand osteoarthritis

Project manager

Ida Bos-Haugen

WP6 - Deciphering long-term outcomes

The Norwegian Antirheumatic Drug Register

Project manager

Tore K. Kvien

WP2 - Phenotyping for personalized medicine

The NORwegian therapeutic DRUg Monitoring study

Project manager

Espen A. Haavardsholm

WP6 - Deciphering long-term outcomes

Gout in Norway

Project manager

Tillmann Uhlig

WP1 - Optimized medical interventions

Switching from originator product to biosimilar in patients with inflammatory diseases of the joints, gut or skin

Project manager

Tore Kvien

WP2 - Phenotyping for personalized medicine

Immunological response to COVID-19 vaccine in patients on immunosuppressive therapy

Project manager

Guro L. Goll

WP2 - Phenotyping for personalized medicine

Rheumatic immune-related adverse events in patients treated with immunotherapy

Project manager

Marte Schrumpf Heiberg

WP6 - Deciphering long-term outcomes

Spondyloarthritis caught early

Project manager

Karen Minde Fagerli

WP2 - Phenotyping for personalized medicine

STratification of acute inflammatory ARThritis

Project manager

Silje Watterdal Syversen

Partners

All rights reserved © REMEDY; Illustration/portrait images © Nicolas Tourrenc/Diakonhjemmet Hospital